AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Astrazeneca (AZN) concluded the recent trading session at $67.25, signifying a -0.74% move from its prior day's close.

Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significan.

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

Ford Motor Company

Barrick Gold

Lockheed Martin

Rio Tinto plc Sponsored

AT&T

Vale S.A.

Blue-chip stocks are associated with a low-beta, stable returns, and passive dividend income for investors. However, not all blue-chip stocks are comparable when it comes to returns over a time-frame.

7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years

FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.

AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication

Bayer AG

Bicycle Therapeutics Plc - ADR

Bristol-Myers

Exelixis

Fusion Pharmaceuticals

Eli Lilly

Merck

Novartis

Takeda Pharmaceutical

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

2 More Potential Biotech Buyout Targets

Occidental Petroleum

In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step.

3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.

Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing

AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.

AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share.

Biotech Stock Soars on AstraZeneca Buyout

AstraZeneca said Tuesday is would acquire Fusion Pharmaceuticals for $2 billion upfront. The biotech stock nearly doubled.

Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover

AstraZeneca PLC (LSE:AZN) is acquiring Canada's Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively 'keep up with Joneses' as it seeks to challenge Novartis, which is blazing a trail in targeted cancer treatment. Fusion specialises in the development of radioconjugates, which focuses on delivering radioactive isotopes directly to cancer cells through precise targeting mechanisms.

AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs have emerged as a promising modali.

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.

AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion

AstraZeneca PLC (LSE:AZN) is acquiring clinical-stage oncology group Fusion Pharmaceuticals in a $2.4 billion (£1.9 billion) deal. The offer represents a massive 126% premium to Nasdaq-listed Fusion's Monday closing price.

AstraZeneca to buy Fusion Pharma in $2.4bln deal

AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.

AstraZeneca to buy Fusion Pharma for $2 billion in cash

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.

AstraZeneca to cap US out-of-pocket costs for inhalers to $35

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease (COPD), including those who are uninsured and underinsured. Pascal Soriot, Chief Executive Officer, AstraZeneca.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Advanced Micro Devices

Amazon

ASML Hld

NVIDIA

Novo Nordisk

Toyota Motor

By definition, mega-cap stocks are those which possess a market capitalization above $200 billion. So, investors seeking to turn $10,000 into $1 million through Mega cap companies will be choosing from the top 60 companies on this list.

7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million

AstraZeneca PLC (LSE:AZN)'s £780 million takeover of France-based Amolyt Pharma on Thursday failed to tempt much of a reaction from Deutsche Bank analysts. According to the bank, the acquisition “is sufficiently modest to pass under the radar without any visible impact on leverage or profit and losses”.

AstraZeneca Amolyt Pharma takeover ‘sufficiently modest' - analysts

AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, boosting its pipeline of drugs to treat rare diseases.

AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline

AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.

AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion

PARIS--(BUSINESS WIRE)-- #VC--Sofinnova Partners announced that its portfolio company, Amolyt Pharma, has entered into a definitive agreement with AstraZeneca for its acquisition.

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

News for AstraZeneca Stock (AZN)